AI-assisted, human-published
01/05/2024 /Funding Events
Revagenix Bolsters Board and Concludes Series B Funding Round
Revagenix,a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, appoints new board members and secures Series B funding round closure.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com